Literature DB >> 20838208

Prolonged survival of a patient with cervical intramedullary glioblastoma multiforme treated with total resection, radiation therapy, and temozolomide.

Han-Min Tseng1, Lu-Ting Kuo, Huang-Chun Lien, Kao-Lang Liu, Mu-Tai Liu, Chao-Yuan Huang.   

Abstract

We report a case of prolonged survival in a patient with cervical intramedullary glioblastoma multiforme (GBM) treated with total resection, radiotherapy, and temozolomide. A 26-year-old woman complaining of midline lower cervical pain, insidiously progressive motor weakness, paresthesia, and urinary incontinence was admitted to our institution. MRI showed an intramedullary mass lesion in the C2-C6 level, which was considered to be an ependymoma or astrocytoma. Total resection of the tumor was performed at the C2-C6 level by laminoplasty with miniplate, followed by chemoradiotherapy (focal irradiation dose of 5000, at 200 cGy per fraction for over a period of 5 weeks) with concomitant temozolomide (75 mg/m2). Histologic examination of the resected tumor confirmed GBM. The tumor consisted of a markedly pleomorphic neoplasm measuring 4.6 cm×2.6 cm×1.7 cm and characterized by necrosis, atypical mitotic figures, and endothelial proliferation. Postoperative MRI showed a centrally located, postoperative cavity at the C2-C6 level. Recurrence in the cervical spine without brain GBM metastasis was identified 25 months after operation, and temozolomide chemotherapy was reinitiated; however, the tumor progressed, and the patient died 33 months after operation. We suggest that, in addition to potential factors of tumor biology, multimodal treatment consisting of total resection of intramedullary GBM coupled with radiation therapy and temozolomide may have prolonged the survival of this patient.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20838208     DOI: 10.1097/CAD.0b013e32833f2a09

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  6 in total

1.  Radiotherapy of spinal cord gliomas : A retrospective mono-institutional analysis.

Authors:  Stefanie Corradini; Indrawati Hadi; Vinzent Hankel; Lorenz Ertl; Ute Ganswindt; Claus Belka; Maximilian Niyazi
Journal:  Strahlenther Onkol       Date:  2015-10-30       Impact factor: 3.621

Review 2.  Current Management and Treatment Modalities for Intramedullary Spinal Cord Tumors.

Authors:  Rupa G Juthani; Mark H Bilsky; Michael A Vogelbaum
Journal:  Curr Treat Options Oncol       Date:  2015-08

3.  Temozolomide or bevacizumab for spinal cord high-grade gliomas.

Authors:  Thomas J Kaley; Ijah Mondesire-Crump; Igor T Gavrilovic
Journal:  J Neurooncol       Date:  2012-06-08       Impact factor: 4.130

4.  Marked functional improvement after combined chemoradiotherapy for cervical spine glioblastoma causing quadriparesis in an adolescent.

Authors:  Peter Kar Han Lau; Gabriel Lee; Michael Bynevelt; Anna K Nowak
Journal:  BMJ Case Rep       Date:  2014-02-11

5.  A Prospective Clinical Study on MGMT Protein Expression and the Effect of Gene Promoter Methylation on Sensitivity to Chemotherapeutics in Spinal Glioma.

Authors:  Peng Sun; Duo-Jiao Fan; Tao Fan; Xin Li; Xue-Ling Qi; Xin-Gang Zhao; Qi-Fei Gai
Journal:  J Inflamm Res       Date:  2021-09-18

6.  Spinal Intradural Intramedullary Dissemination in the Absence of Intracranial Relapse of a Previously Radically Treated Temporal Lobe Glioblastoma Multiforme.

Authors:  Lucas Serrano; Eleftherios Archavlis; Elke Januschek; Pavel Timofeev; Peter Ulrich
Journal:  Case Rep Oncol       Date:  2017-03-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.